12/10
08:58 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BTIG Research. They set a "buy" rating and a $60.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BTIG Research. They set a "buy" rating and a $60.00 price target on the stock.
12/6
08:06 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $55.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $55.00 price target on the stock.
12/2
08:06 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $57.00 price target on the stock, up previously from $38.00.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $57.00 price target on the stock, up previously from $38.00.
11/26
07:05 am
kymr
Kymera Therapeutics to Participate in Upcoming December Investor Conferences [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Participate in Upcoming December Investor Conferences [Yahoo! Finance]
11/26
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
11/18
08:50 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
High
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
11/6
05:34 pm
kymr
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Low
Report
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
11/6
08:06 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
11/5
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
11/4
11:22 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.
11/4
06:23 am
kymr
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report [Yahoo! Finance]
11/1
03:39 pm
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Guggenheim from $45.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Guggenheim from $45.00 to $52.00. They now have a "buy" rating on the stock.
11/1
11:55 am
kymr
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
Low
Report
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
11/1
11:27 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $53.00 price target on the stock, down previously from $54.00.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $53.00 price target on the stock, down previously from $54.00.
11/1
10:55 am
kymr
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Low
Report
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
10/31
07:30 am
kymr
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Low
Report
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
10/24
07:00 am
kymr
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
Low
Report
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
10/23
07:15 am
kymr
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Medium
Report
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
10/23
07:00 am
kymr
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Medium
Report
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
10/9
02:51 pm
kymr
Kymera gets FDA clearance for Phase 1 testing of KT-621 [Seeking Alpha]
Neutral
Report
Kymera gets FDA clearance for Phase 1 testing of KT-621 [Seeking Alpha]
10/9
07:00 am
kymr
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Low
Report
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
10/6
03:00 pm
kymr
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors [Seeking Alpha]
Low
Report
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors [Seeking Alpha]
9/27
09:16 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $52.00 to $56.00. They now have an "outperform" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $52.00 to $56.00. They now have an "outperform" rating on the stock.
9/25
07:00 am
kymr
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Low
Report
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress